These results are confirmed by analyses of datasets from human prostate tumors and reveal a specific and significant direct correlation of PTOV1 with ALDH1A1 and CCNG2. These findings identify PTOV1 as a novel potential therapeutic target for patients with metastatic prostate cancer. This evidence concerns the gene PTOV1 and metastatic prostate carcinoma.